MARKET

IOVA

IOVA

Iovance Biotherp
NASDAQ
6.26
+0.19
+3.13%
After Hours: 6.19 -0.07 -1.12% 19:29 12/01 EST
OPEN
6.05
PREV CLOSE
6.07
HIGH
6.28
LOW
5.76
VOLUME
6.38M
TURNOVER
0
52 WEEK HIGH
9.36
52 WEEK LOW
3.210
MARKET CAP
1.60B
P/E (TTM)
-3.0114
1D
5D
1M
3M
1Y
5Y
Notable Thursday Option Activity: VOYA, NUVL, IOVA
NASDAQ · 2d ago
Weekly Report: what happened at IOVA last week (1120-1124)?
Weekly Report · 5d ago
Goldman Sachs Says These 2 Healthcare Stocks Have up to 130% Upside Potential
TipRanks · 11/22 01:21
Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Renew energy global plc shares rose 13.6% to $6.74 on monday. Renew energy posted quarterly sales of $345.00 million. Bruush oral care inc. Shares jumped 147.2% after reporting strong quarterly sales. Javier milei's victory in argentina's presidential election sparked a rally in argentine adrs.
Benzinga · 11/20 19:35
Crude Oil Gains Over 2%; PaxMedica Shares Plunge
The dow jones index traded up 0.34%, the nasdaq rose 0.80% and the s&p 500 gained 0.43%. The index of leading economic indicators fell 0.8% in october. Information technology shares surged by 0. 8% on monday.
Benzinga · 11/20 17:09
IOVA, YPF and SMR are among pre market gainers
Logicmark, ypf and smr are among pre market gainers. Alzamend neuro receives approval for a clinical trial of a new lithium drug candidate. Iova, lgmk and gdc are among the other companies on the move in the pre market.
Seeking Alpha · 11/20 13:22
Weekly Report: what happened at IOVA last week (1113-1117)?
Weekly Report · 11/20 10:22
Goldman Sachs Initiates Coverage On Iovance Biotherapeutics with Buy Rating, Announces Price Target of $12
Benzinga · 11/20 09:46
More
About IOVA
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company, which commercializes autologous T-cell therapy to address solid tumor cancer. It develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, lifileucel, is being developed in advanced, or metastatic or unresectable, melanoma, as well as in other indications. Lifileucel is investigated in two consecutive cohorts in a clinical trial of advanced melanoma patients post-anti-PD-1 therapy, including in a prospectively defined pivotal cohort. It has initiated Phase III clinical trial of lifileucel in combination with pembrolizumab, TILVANCE-301. The Company is also pursuing registrational strategies for lifileucel in advanced cervical cancer and for its TIL therapy, LN-145, in metastatic non-small cell lung cancer. Its first genetically modified, PD-1 inactivated TIL therapy, IOV-4001, is under Phase I/II clinical trial, IOV-GM1-201.

Webull offers Iovance Biotherapeutics Inc stock information, including NASDAQ: IOVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IOVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IOVA stock methods without spending real money on the virtual paper trading platform.